16:05 EDT Lisata Therapeutics files $150M mixed securities shelf
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LSTA:
- Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
- Lisata, Qilu announce first patient treated in Phase 2 trial of LSTA1
- Lisata Therapeutics Elevates James Nisco to Senior VP Finance
- Lisata Therapeutics announces Orphan Drug designation for LSTA1
- Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma